Clinical Trials Logo
  1. Home
  2. Post-Menopausal Osteoporosis
  3. NCT00081653

A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva

Post-Menopausal Osteoporosis Clinical Trial

Official title:
Double-blind, Partially Randomized, Parallel Group, Multicenter Study to Assess the Efficacy and Safety of 100 mg and 150 mg Monthly Oral Ibandronate in Women With Postmenopausal Osteoporosis Having Completed the Phase III Oral Ibandronate Trial BM16549

Clinical Trial Summary

This 2 arm study will assess the long-term efficacy and safety of oral treatment with 100mg or 150mg Bonviva in women with post-menopausal osteoporosis who have previously completed Bonviva study BM16549 (MOBILE study). Patients will receive Bonviva either 100mg po monthly, or 150mg po monthly. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00081653
Study type Interventional
Source Hoffmann-La Roche
Contact
Status Completed
Phase Phase 4
Start date May 2004
Completion date May 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT01224717 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women Phase 1
Completed NCT00551174 - A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment Phase 4
Completed NCT00984893 - Intra-venous Zoledronic Acid Once Yearly N/A
Withdrawn NCT01826656 - Bone Healing in Healthy and Post-menopausal Osteoporotic Women N/A
Completed NCT00718861 - 3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs Phase 3
Completed NCT00503113 - A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease. Phase 4
Completed NCT00150969 - Vitamin K Supplementation in Post-Menopausal Osteopenia Phase 3
Completed NCT03432533 - A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis Phase 3
Completed NCT00545779 - BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy. Phase 4
Completed NCT00533650 - Proof of Concept (Bone Resorption/Bone Mineral Density) Study (0429-005) Phase 2
Active, not recruiting NCT01232647 - Vitamin K as Additive Treatment in Osteoporosis Phase 2/Phase 3
Completed NCT00666627 - Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects Phase 2